Institute Of Diabetes Endocrinology And Adiposity Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 09-07-2024
- Paid Up Capital ₹ 1.45 Cr
as on 09-07-2024
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue -9.27%
(FY 2018)
- Profit -32.28%
(FY 2018)
- Ebitda -38.29%
(FY 2018)
- Net Worth -59.54%
(FY 2018)
- Total Assets -53.80%
(FY 2018)
About Institute Of Diabetes Endocrinology And Adiposity
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 1.45 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shyam Kalavalapalli, Durga Kalavalapalli, and Srinivas Paidipally serve as directors at the Company.
- CIN/LLPIN
U85100TG2014PTC096244
- Company No.
096244
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2014
- Date of AGM
09 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
Who are the key members and board of directors at Institute Of Diabetes Endocrinology And Adiposity?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Durga Kalavalapalli  | Director | 05-Nov-2014 | Current |
| Shyam Kalavalapalli | Director | 05-Nov-2014 | Current |
| Srinivas Paidipally | Director | 05-Nov-2014 | Current |
Financial Performance and Corporate Structure Insights of Institute Of Diabetes Endocrinology And Adiposity.
Institute Of Diabetes Endocrinology And Adiposity Private Limited, for the financial year ended 2018, experienced Minor drop in revenue, with a 9.27% decrease. The company also saw a substantial fall in profitability, with a 32.28% decrease in profit. The company's net worth observed a substantial decline by a decrease of 59.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Institute Of Diabetes Endocrinology And Adiposity?
In 2018, Institute Of Diabetes Endocrinology And Adiposity had a promoter holding of 86.11% and a public holding of 13.89%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Institute Of Diabetes Endocrinology And Adiposity?
Unlock and access historical data on people associated with Institute Of Diabetes Endocrinology And Adiposity, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Institute Of Diabetes Endocrinology And Adiposity, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Institute Of Diabetes Endocrinology And Adiposity's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
